Tumor plasmacytoid dendritic cells and tumor immunity
Tumor plasmacytoid dendritic cells and tumor immunity
批准号:
7282136
负责人:
WEIPING ZOU
金额:
$12.77万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-07-01 至 2008-04-30
关键词:
T lymphocytecell cell interactioncell growth regulationcell proliferationcellular immunityclinical researchdendritic cellsfemaleflow cytometryhelper T lymphocytehuman subjectimmunosuppressioninterleukin 10leukocyte activation /transformationlymph nodesmalignant ascitesneoplasm /cancer immunologyovary neoplasmspatient oriented researchsuppressor T lymphocytesurface antigenstumor antigenswomen&aposs health
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Although most cancers possess tumor-associated antigens (TAA) that can serve as targets of the immune system, immunity is not effectively induced in most tumor-bearing hosts. Dysregulation of dendritic cell (DC) differentiation, function and trafficking may contribute to tumor immunopathogenesis. Malignant ascites contains viable tumor and immune cells, which we used as a model for the tumor environment. We identified a significant population of PDC, not MDC, in malignant ascites of patients with ovarian carcinoma. Our work demonstrate that tumor PDC induce TAA-specific IL-10+CCR7+CD8+ T cells. These T cells migrate with lymphoid homing molecule CCR7, and suppress MDC mediated TAA-specific protective tumor immunity. Further, MDC cannot recover the suppressive effects. More importantly, we show that tumor-mediated upregulation of PDC B7-H1 contributes to detrimental immunity induced by tumor PDC. We now extend these observations, and further demonstrate in detail the nature of TAA-specific T cell immunity induced by tumor PDC, and the underlying mechanisms.
There exists a significant amount of PDC in tumor ascites. Tumor ascites harbors predominantly memory T cells. By examining the interaction between tumor ascites TAA-expressing PDC and tumor memory T cells, Aim 1 is to test our hypothesis that tumor PDC induce TAA-specific suppressive memory CD8+ T cell immunity.
Lymph nodes (LNs) are the central priming sites for DC to initiate T cell immunity. LNs harbor predominantly naive T cells. Draining tumor LN-PDC co-localized with naive T cells. By examining the interaction between TAA expressing LN-PDC and LN naive T cells, Aim 2 is to test our hypothesis that draining tumor LNPDC induce TAA-specific suppressive naive CD8+ T cell immunity.
B7-H1 is a member of the B7 T cell costimulatory family that induces T cell IL-10 and mediates tolerance/anergy. Tumor PDC highly express B7-H1 whose regulation and functional significance is unknown. Aim 3 is to test our hypothesis that tumor PDC B7-HI contributes to induce TAA-specific suppressive CD8+ T cell immunity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CTL-killing capacity and cancer stiffness in cancer immunity and therapy
-
批准号:10548120
-
项目类别:
-
资助金额:$63.44万
-
财政年份:2022
-
负责人:WEIPING ZOU
-
依托单位:
CTL-killing capacity and cancer stiffness in cancer immunity and therapy
-
批准号:10274980
-
项目类别:
-
资助金额:$64.74万
-
财政年份:2022
-
负责人:WEIPING ZOU
-
依托单位:
Regulatory T cells in cancer therapy
-
批准号:10209436
-
项目类别:
-
资助金额:$64.73万
-
财政年份:2021
-
负责人:WEIPING ZOU
-
依托单位:
Regulatory T cells in cancer therapy
-
批准号:10361528
-
项目类别:
-
资助金额:$63.44万
-
财政年份:2021
-
负责人:WEIPING ZOU
-
依托单位:
Regulatory T cells in cancer therapy
-
批准号:10652255
-
项目类别:
-
资助金额:$63.43万
-
财政年份:2021
-
负责人:WEIPING ZOU
-
依托单位:
Metabolic impact on T cell-mediated cancer immunity and therapy
-
批准号:10430013
-
项目类别:
-
资助金额:$63.35万
-
财政年份:2020
-
负责人:WEIPING ZOU
-
依托单位:
Metabolic impact on T cell-mediated cancer immunity and therapy
-
批准号:10159227
-
项目类别:
-
资助金额:$64.64万
-
财政年份:2020
-
负责人:WEIPING ZOU
-
依托单位:
Metabolic impact on T cell-mediated cancer immunity and therapy
-
批准号:10650404
-
项目类别:
-
资助金额:$63.34万
-
财政年份:2020
-
负责人:WEIPING ZOU
-
依托单位:
Ovarian Cancer Epigenetics, Immunity and Therapy
-
批准号:10408767
-
项目类别:
-
资助金额:$59.88万
-
财政年份:2018
-
负责人:WEIPING ZOU
-
依托单位:
Ovarian Cancer Epigenetics, Immunity and Therapy
-
批准号:10163133
-
项目类别:
-
资助金额:$62.0万
-
财政年份:2018
-
负责人:WEIPING ZOU
-
依托单位:
Immune Impact on Cancer Chemoresistance
-
批准号:9207664
-
项目类别:
-
资助金额:$60.99万
-
财政年份:2017
-
负责人:WEIPING ZOU
-
依托单位:
Naive T cells in Cancer Immune Evasion and Immunotherapy
-
批准号:10199954
-
项目类别:
-
资助金额:$64.72万
-
财政年份:2017
-
负责人:WEIPING ZOU
-
依托单位:
Naive T cells in Cancer Immune Evasion and Immunotherapy
-
批准号:10411383
-
项目类别:
-
资助金额:$8.1万
-
财政年份:2017
-
负责人:WEIPING ZOU
-
依托单位:
Naive T cells in Cancer Immune Evasion and Immunotherapy
-
批准号:9348840
-
项目类别:
-
资助金额:$61.38万
-
财政年份:2017
-
负责人:WEIPING ZOU
-
依托单位:
Immune Impact on Cancer Chemoresistance
-
批准号:9397538
-
项目类别:
-
资助金额:$61.19万
-
财政年份:2017
-
负责人:WEIPING ZOU
-
依托单位:
Naive T cells in Cancer Immune Evasion and Immunotherapy
-
批准号:9752498
-
项目类别:
-
资助金额:$61.47万
-
财政年份:2017
-
负责人:WEIPING ZOU
-
依托单位:
MDSCs in Ovarian Cancer
-
批准号:9288150
-
项目类别:
-
资助金额:$49.83万
-
财政年份:2015
-
负责人:WEIPING ZOU
-
依托单位:
Effector T Cell Trafficking in Ovarian Cancer
-
批准号:9014531
-
项目类别:
-
资助金额:$51.4万
-
财政年份:2015
-
负责人:WEIPING ZOU
-
依托单位:
Effector T Cell Trafficking in Ovarian Cancer
-
批准号:9220730
-
项目类别:
-
资助金额:$51.4万
-
财政年份:2015
-
负责人:WEIPING ZOU
-
依托单位:
Immune Regulation in the Microenvironment of Oropharyngeal Cancer
-
批准号:8577165
-
项目类别:
-
资助金额:$53.47万
-
财政年份:2013
-
负责人:WEIPING ZOU
-
依托单位:
海外基金